{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:21:09Z","timestamp":1780626069673,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.yebeh.2022.108614","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T11:05:04Z","timestamp":1645441504000},"page":"108614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Clinical impact of the dose and blood concentration of lacosamide in Japanese pediatric patients with epilepsy: A cohort study"],"prefix":"10.1016","volume":"129","author":[{"given":"Nobutsune","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Izumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2022.108614_b0005","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","article-title":"Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies","volume":"88","author":"Fiest","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108614_b0010","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108614_b0015","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.yebeh.2011.08.032","article-title":"Add-on lacosamide: A retrospective study on the relationship between serum concentration, dosage, and adverse events","volume":"22","author":"Hillenbrand","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108614_b0020","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.seizure.2017.09.019","article-title":"Safety of intravenous lacosamide in critically ill children","volume":"52","author":"Welsh","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108614_b0025","doi-asserted-by":"crossref","first-page":"100402","DOI":"10.1016\/j.ebr.2020.100402","article-title":"The effect of lacosamide on psychiatric comorbidities in patients with epilepsy","volume":"14","author":"Hasegawa","year":"2020","journal-title":"Epilepsy Behav Rep"},{"key":"10.1016\/j.yebeh.2022.108614_b0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.seizure.2018.01.014","article-title":"Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: A systematic review","volume":"56","author":"Ortiz de la Rosa","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108614_b0035","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/epi.13671","article-title":"Instruction manual for the ILAE 2017 operational classification of seizure types","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108614_b0040","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1684\/epd.2015.0782","article-title":"Efficacy and safety of lacosamide as an adjunctive therapy for refractory focal epilepsy in paediatric patients: a retrospective single-centre study","volume":"17","author":"Toupin","year":"2015","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2022.108614_b0045","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejpn.2013.08.006","article-title":"Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy","volume":"18","author":"Grosso","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2022.108614_b0050","doi-asserted-by":"crossref","first-page":"e1212","DOI":"10.1212\/WNL.0000000000008126","article-title":"Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures","volume":"93","author":"Farkas","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108614_b0055","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.seizure.2020.04.016","article-title":"Efficacy and tolerability of treatment with lacosamide in children: Postmarketing experience from the Middle East","volume":"79","author":"Hmaimess","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108614_b0060","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/epi.14071","article-title":"Long-term efficacy of add-on lacosamide treatment in children and adolescents with refractory epilepsies: A single-center observational study","volume":"59","author":"Rosati","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108614_b0065","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.seizure.2019.05.016","article-title":"Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures \u2013 An open-label trial","volume":"71","author":"Ferreira","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108614_b0070","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.yebeh.2017.11.024","article-title":"The effectiveness and safety of lacosamide in children with epilepsy in a clinical practice setting","volume":"79","author":"Sanmart\u00ed-Vilaplana","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108614_b0075","doi-asserted-by":"crossref","first-page":"116601","DOI":"10.1016\/j.jns.2019.116601","article-title":"Efficacy upon 12-weeks after achievement of maximal dose and tolerability of lacosamide as an adjunctive therapy in epilepsy: Real world clinical experience","volume":"409","author":"Chang","year":"2020","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.yebeh.2022.108614_b0080","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/FTD.0000000000000764","article-title":"Therapeutic monitoring of lacosamide in Japanese patients with epilepsy: clinical response, tolerability, and optimal therapeutic range","volume":"42","author":"Yamamoto","year":"2020","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2022.108614_b0085","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/FTD.0b013e318290eacc","article-title":"Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs","volume":"35","author":"Contin","year":"2013","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2022.108614_b0090","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/FTD.0000000000000599","article-title":"Pharmacokinetic variability and clinical use of lacosamide in children and adolescents in Denmark and Norway","volume":"41","author":"Burns","year":"2019","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2022.108614_b0095","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11636260-000000000-00000","article-title":"Efficacy and tolerability of lacosamide in the concomitant treatment of 130 patients under 16 years of age with refractory epilepsy","volume":"12","author":"Casas-Fern\u00e1ndez","year":"2012","journal-title":"Drugs R D"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022000634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022000634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:44:48Z","timestamp":1761504288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505022000634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":19,"alternative-id":["S1525505022000634"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108614","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical impact of the dose and blood concentration of lacosamide in Japanese pediatric patients with epilepsy: A cohort study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108614"}}